Net loss for the three-month period ended September 30, 2009, totalled $148,000, compared with $283,000 for the corresponding period in 2008. For the nine-month period ended September 30, 2009, net loss was $983,000, compared with $1,001,000 for the corresponding period last year.
As at September 30, 2009, the Company's cash and cash equivalents amounted to $46,000.
Subsequent to the end of the quarter, the Company completed a qualifying transaction on October 28, 2009 and concurrently with the merger, completed financings relating to a Private Placement and debt conversion, in the gross amount of CDN$2,200,000. Upon the Exchange's issuance of its Final Exchange Bulletin approving the qualifying transaction, the Company ceased to be a Capital Pool Company, and its trading symbol on the TSX-Venture is now "HTL".
The financial statements are available on www.sedar.com.
About Hamilton Thorne Ltd.
Hamilton Thorne's advanced laser systems and instruments are rapidly emerging as the dominant products to facilitate precise procedures in the stem cell research and fertility clinic markets. Hamilton Thorne's lead products, the ZILOS-tk and XYClone laser systems, attach to standard inverted microscopes and operate as robotic micro-surgeons, significantly reducing time and increasing efficiency in key in-vitro fertilization, stem cell, embryo, reproductive toxicology and living cell procedures.
Hamilton Thorne's growing customer base includes pharmaceutical companies, biotechn
|Copyright©2009 PR Newswire.|
All rights reserved